Clinical Trials Logo

Clinical Trial Summary

The main purpose of this study is to assess the change in clinician global impression after 24 weeks of treatment with QTORIN 3.9% Rapamycin Anhydrous Gel compared to placebo in approximately 50 participants with microcystic lymphatic malformations.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06239480
Study type Interventional
Source Palvella Therapeutics, Inc.
Contact Kathy Goin
Phone 484-612-2335
Email kathy.goin@palvellatx.com
Status Not yet recruiting
Phase Phase 3
Start date July 2024
Completion date January 2026

See also
  Status Clinical Trial Phase
Recruiting NCT05050149 - Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations Phase 2
Active, not recruiting NCT00975819 - Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies Phase 2
Recruiting NCT06160739 - Role of Sirolimus in Treatment of Microcystic , Mixed Lymphatic and Vascular Malformations